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Abstract
The supply of new diagnostics and treatments is insufficient to 
keep up with the increase in antimicrobial resistance (AMR) and 
multidrug resistance (MDR) as older medicines are used more 
widely and microbes develop resistance to them. At the same time, 
significant quantities of antibiotics are used on patients and animals 
that do not need them, while others who do need them lack access.
Effective responses to AMR/MDR require effort by both the public and 
private sectors to develop and disseminate new diagnostics, vaccines 
and treatments on a global scale, as well as to adapt them to local needs. 
This calls for good governance to identify priorities, raise awareness and 
ensure effective stewardship at global, regional and national levels to 
minimize the development of resistance. Failure to act appropriately in 
one country will adversely impact all countries as resistance travels fast. 
Based on a review of recent literature, this WIPO Global 
Challenges Report includes a broad overview of current 
approaches and consortia designed to meet the challenge of 
research and development (R&D) investment for new treatments. 
It also examines patent applications by both the public and 
the private sectors as an indicator of innovative activity. 
This report finds that there is a need to address the unique market 
challenges and specific uncertainties associated with the development 
of new diagnostics and treatments, where current approaches are not 
optimal. An effective global framework that achieves the necessary 
political support while ensuring effective local implementation is 
crucial. There is an opportunity to complement this work by formulating 
mechanisms that drive innovation for results to incentivize success, 
while feeding expertise and experience into stewardship and access 
efforts. Intellectual property (IP) could be used in a constructive 
manner as one element in any reward or prize system for AMR/MDR 
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In 1928 a piece of mold contaminated a petri dish, killing bacteria under examination. This led Alexander 
Fleming to one of the greatest discoveries in modern medicine, and within 12 years Fleming and others 
turned this finding into a wonderdrug that could cure patients with bacterial infections. Common – yet 
frequently deadly – illnesses such as pneumonia and tuberculosis (TB) could be treated effectively. 
But bacteria and other pathogens are also great innovators and are adept at developing resistance 
to antibiotic medicines. Overuse, misuse, and/or lack of patient adherence to complete the course 
have led to ever-increasing levels of resistance to antibiotic treatment. Resistance has become par-
ticularly problematic in recent years because the pace at which novel antibiotics are being discovered 
has slowed drastically while antibiotic use continues to rise. The routine addition of antibiotics in food 
animal production significantly increases the probably of resistance.1 The great strides made over the 
past few decades to effectively treat HIV/AIDS, TB and malaria could be reversed, leading to these 
and other diseases spiralling out of control. Figure 1 shows the impact of antibiotics on public health. It 
compares the 10 leading causes of death as a percentage of all deaths in the United States of America 
(USA) in 1900 and 1997. Major and minor surgery could once again result in fatal infections and many 
treatments that have become commonplace would not be possible without high risk. AMR/MDR there-
fore threatens many of the most important medical advances made this century. But the impact goes 
far beyond health systems. A conservative estimate is that AMR currently accounts for over 700,000 
deaths annually, but this could rise to 10 million in 2050 if not effectively addressed.2
This research brief sets out the approaches currently taken at the highest political level, right through 
to the practical steps being taken in the fight to overcome the microbes, and tries to identify oppor-
tunities for innovation and intellectual property (IP) systems to play an active role in the global effort. 
1 Collignon et al., “World Health Organization ranking of antimicrobials according to their importance in human medicine: 
a critical step for developing risk management strategies to control antimicrobial resistance from food animal production”, 
Clinical Infectious Diseases, July 20, 2016.
2 Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, Review on Antimicrobial Resistance, 
May 2016; the plausibility of these estimations has been questioned by de Kraker, M.E.A., A.J. Stewardson and S. Harbarth, 
2016, “Will 10 million people die a year due to antimicrobial resistance by 2050?”, PLoS Med 13(11): e1002184. doi:10.1371/
journal.pmed.1002184; available at https://doi.org/10.1371/journal.pmed.1002184 
Figure 1: 
The impact of the introduction of antibiotics on public health: the 10 leading 
causes of death as a percentage of all deaths in the USA in 1900 and 1997
Source: Mitchell L. Cohen, “Changing patterns of infectious disease”, Nature 406, 762-767, August 17, 2000.
32. High-level literature 
review
Although there has been a dramatic increase in the atten-
tion and focus on AMR/MDR over the past five years or so 
(leading to a number of high-level political declarations), the 
European Union (EU) and the USA had already established 
high-level measures to guide the use of antibiotics. 
• On June 8, 1999, the Council of the European Union adopt-
ed a Resolution on antibiotic resistance entitled A strate-
gy against the microbial threat,3 which was followed by a 
Council recommendation on November 15, 2001 on The 
prudent use of antimicrobial agents in human medicine.4 
• A US and EU Summit in 2009 declared, inter alia, “To 
establish a transatlantic task force on urgent antimicrobi-
al resistance issues focused on appropriate therapeutic 
use of antimicrobial drugs in the medical and veterinary 
communities, prevention of both healthcare and communi-
ty-associated drug-resistant infections, and strategies for 
improving the pipeline of new antimicrobial drugs, which 
could be better addressed by intensified cooperation 
between us.”5 This led to the creation of the Transatlantic 
Task Force on Antimicrobial Resistance (TATFAR),6 which 
seeks to address the above mandate. In its 2014 progress 
report7 the Task Force highlighted the ongoing work in the 
delivery of recommendations under three key themes:
1. appropriate therapeutic use in human and veterinary 
medicine
2. prevention of drug-resistant infections
3. strategies for improving the pipeline of new antimicro-
bial drugs.
• A paper by the Commission of the Organisation for Economic 
Co-operation and Development (OECD) lays out the issues 
from the perspective of the G7 countries and beyond.8 The 
summary includes the themes as identified by TATFAR but 
makes further recommendations for policymakers:
1. Strengthening existing surveillance and monitoring 
systems and improving statistics on the consumption 
of antimicrobials.
2. The adoption of a globally agreed set of measurable 
targets related to the incidence of AMR, as well as to 
the efficient use of new antibiotics, would provide polit-
ical impetus to address AMR.
3 The Council of the European Union, A strategy against the microbial threat, Resolution no. 1999/C and 195/01.
4 The Council of the European Union, The prudent use of antimicrobial agents in human medicine, Resolution no. 2002/77/EC.
5 2009 EU-US Summit Declaration (p. 3), November 3, 2009.
6 Transatlantic Taskforce on Antimicrobial Resistance; available at www.cdc.gov/drugresistance/tatfar 
7 Transatlantic Taskforce on Antimicrobial Resistance: Progress Report, May 2014; available at http://www.cdc.gov/drugresistance/pdf/tatfar-
progress_report_2014.pdf 
8 Michele Cecchini, Julia Langer and Luke Slawomirski, Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options 
for Action, OECD Report, 2015. 
9 Global Health Action Plan on Antimicrobial Resistance, WHO Report, Geneva, Switzerland, 2015; available at http://apps.who.int/iris/
bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1 
10 Sixty-eighth World Health Assembly, agenda item 15.1, Global Action Plan on Antimicrobial Resistance, A68/A/CONF./1 Rev.1, May 25, 2015; 
available at http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_ACONF1Rev1-en.pdf?ua=1 
3. Countries should strengthen their ongoing efforts to 
facilitate the upscaling of practices of proven effec-
tiveness and efficiency at national level (for example 
stewardship programs, educational campaigns). 
4. A concerted international approach to foster innovation, 
as well as basic research in the antimicrobial sector, 
is crucial to lower many barriers that currently hinder 
research and development (R&D), and to increase the 
productivity of research at the global level. 
5. The OECD, with its distinctive cross-sectoral expertise, 
is in a unique position to help G7 countries and their 
G20 partners tackle AMR. The OECD can provide a 
forum where governments can discuss, develop and 
coordinate new strategies for prudent antimicrobial use 
in human medicine and agriculture. The OECD can also 
evaluate the detrimental economic impact caused by 
AMR. Finally, it can review and assess the most prom-
ising innovative actions to tackle inappropriate use of 
antimicrobials and overcome barriers to innovation.
OECD Recommendation 4 states that both upstream and 
downstream economic incentives should be combined and 
should aim to de-link development incentives from sales, 
and encourage the participation of small and medium-sized 
enterprises (SMEs) in R&D efforts. A good package would 
include establishing a global collaborative research plat-
form, milestone prizes and grants, patent buyouts, and a 
globally coordinated approach to clinical trials.
• The World Health Organization (WHO) has recently upscaled 
effort on AMR and its Global Plan of Action on AMR9 was 
adopted in 2015,10 after the issue had been referred to in 
a number of previous World Health Assembly Resolutions. 
The Resolution mandates WHO, inter alia: 
“[...]
(2) to ensure that all relevant parts of the Organization, at 
headquarters, regional and country levels, are actively 
engaged and coordinated in promoting work on containing 
antimicrobial resistance, including through the tracking of 
resource flows for research and development on antimi-
crobial resistance in the new global health research and 
development observatory; 
[...]
(5) to develop and implement, in consultation with Member 
States and relevant partners, an integrated global pro-
gram for surveillance of antimicrobial resistance across 
all sectors, in line with the global action plan;
4(6) to establish a network of WHO Collaborating Centres to 
support surveillance of antimicrobial resistance and qual-
ity assessment in each WHO region;
(7) to develop, in consultation with Member States and relevant 
partners, options for establishing a global development 
and stewardship framework to support the development, 
control, distribution and appropriate use of new antimi-
crobial medicines, diagnostic tools, vaccines and other 
interventions, while preserving existing antimicrobial med-
icines, and promoting affordable access to existing and 
new antimicrobial medicines and diagnostic tools, taking 
into account the needs of all countries, and in line with 
the global action plan on antimicrobial resistance, and to 
report to the sixty-ninth World Health Assembly;
[...]”
• In order to implement the suggestion of the Action Plan to 
create new partnerships for the development and conser-
vation of antibiotics, WHO with the Drugs for Neglected 
Diseases initiative (DNDi) have jointly launched the Global 
Antibiotic Research & Development Partnership, which is 
discussed in greater detail below. 
• The Uppsala Health Summit in June 2015 tackled the full 
range of issues, including the need for access – not excess 
– when it comes to the use of antibiotics, collaborative 
innovation models, and global governance. They highlight-
ed the crucial role of vaccines in preventing disease and 
diagnostics in establishing what constitutes appropriate 
use of antibiotics.11 
• In October 2015, the G7 Health Ministers met to discuss 
AMR and Ebola. Their Declaration12 fully supports the WHO 
Action Plan and identifies the need to explore the setting-up 
of a global antibiotics product development partnership, 
mentioning the WHO/DNDi proposed initiative. 
• In addition to the political focus, there are a vast number 
of new publications covering the extent of the threat posed 
by AMR/MDR and possible solutions to address the prob-
lems.13 The Lancet Infectious Disease Commission high-
lighted that, although the causes of AMR are complex, the 
consequences affect everybody in the world.14 
11 Uppsala Health Summit 2015: A World Without Antibiotics, 2015; available at http://www.uppsalahealthsummit.se/
our-summits/a-world-without-antibiotics-2015 
12 Declaration of the G7 Health Ministers, October 8-9, 2015, Berlin; available at http://www.bmg.bund.de/fileadmin/dateien/Downloads/G/G7-Ges.
Minister_2015/G7_Health_Ministers_Declaration_AMR_and_EBOLA.pdf 
13 AMR Control 2015, Overcoming Global Antimicrobial Resistance, The World Alliance Against Antibiotic Resistance (WAAR), 2015.
14 Antibiotic Resistance – The Need for Global Solutions, The Lancet Infectious Diseases Commission, 2013. 
15 Renwick, M.J., D.M. Brogan and E. Mossialos, “A systematic review and critical assessment of incentive strategies for discovery and development of 
novel antibiotics”, The Journal of Antibiotics, 2015. 
16 “Approaches to simulating innovation for development of new antibiotic drugs”, KEI, 2013. 
17 Strategic Research Agenda, Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), December 5, 2015. 
18 Towards a New Global Business Model for Antibiotics – Delinking Revenues from Sales, The Royal Institute of International Affairs, Chatham 
House, October 2015. 
19 https://longitudeprize.org/challenge/antibiotics 
20 Dr. Mathias Bernhard Bonk, Responses to the Antimicrobial Resistance Threat: A Comparative Study of Selected National Strategies and Policies, 
Swiss Federal Office of Public Health (FOPH), Division of International Affairs, May 2015. 
• There have been a number of papers that have reviewed 
and critically assessed incentive strategies for discovery 
and development of new antibiotics.15, 16, 17, 18
• One example of the use of prizes is the United Kingdom 
(UK) Longitude Prize, which offers GBP 10 million to a 
successful researcher.19
• A recent study by the Swiss Federal Office of Public Health 
explores the national AMR strategies of a number of 
European countries (Denmark, France, Germany, Norway, 
Sweden, Switzerland and the UK) as well as South Africa 
and the USA to add additional perspectives. The study 
includes an assessment of the various approaches and 
best practices.20
53. Broad overview of current 
market issues related to AMR/
MDR and trends in R&D for 
new antibiotics covering both 
private and public sectors 
There is a lack of new antibacterial medicines and vaccines as the growth in 
AMR/MDR has been accompanied by a sharp decline in development of new 
treatments. Over the past three decades only two new classes of antibacterial 
medicines have been discovered, compared to 11 in the previous 50 years. The 
number of antibiotics becoming obsolete due to resistance significantly exceeds 
the number of new, approved treatments.21 
The two new classes of treatments relate to pulmonary multidrug-resistant tubercu-
losis (MDR-TB), where drug resistance has been on the rise. The first is Otsuka’s 
delamanid, which was granted approval in 2014 by Japan, the Republic of Korea 
and within the EU (to be used in combination with other anti-TB medicines). In 
November 2014, WHO issued policy guidance on the use of delamanid, to assist 
access in developing countries. The second was Janssen Pharmaceutical’s 
bedaquiline, which was granted approval in Peru, the Philippines, the Republic of 
Korea, the Russian Federation, South Africa and the USA. In 2015 the US Food 
and Drug Administration (FDA) approved ceftolozane/tazobactam (Zerbaxa) by 
Cubist (fully owned by MSD) and Allergan/AstraZeneca’s Avycaz, both for the 
treatment of complicated urinary tract and intra-abdominal infections, as well as 
bacterial pneumonia. 
The introduction of antibiotics and immunization has been a key contributor to 
the reduction of deaths from infectious diseases and has helped to make modern 
medicine possible.
As of September 2016, an estimated 4022 new antibiotic medicines with the potential 
to treat serious bacterial infections are in clinical development for the US market. 
The success rate for clinical drug development is low, and currently only around 
one in five candidates that enter human testing (phase 1 clinical trials) will be 
approved for patients.
Most of the private sector development remains focused on existing classes of 
antibiotics where the risk of failure is significantly lower.23 Table 1 shows the cur-
rent R&D underway by International Federation of Pharmaceutical Manufacturers 
and Associations (IFPMA) member companies (April 2015). To share the risk of 
development, the US Biomedical Advanced Research and Development Authority 
(BARDA) directly supports companies that develop new antibiotics through 
its Broad Spectrum Antimicrobials Program. BARDA, for example, launched 
a Portfolio Partnership with GlaxoSmithKline to support the development of a 
number of new antibiotics.24 
21 Michael S. Kinch, Denton Hoyer, et. al., Yale Center for Molecular Discovery, 2014.
22 Antibiotics Currently in Clinical Development, The Pew Centre, December 2015. 




Current research and development underway by IFPMA member companies,  
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AZ/Actavis CAZ-104 Ceftazidime/Avibactam Small molecule Gram-negative Phase 3
CXL-104 Avibactam/Ceftaroline Small molecule Gram-negative Phase 2 
AZ CAZ-104 Ceftazidime/Avibactam Small molecule Gram-negative Phase 3
CXL-104 Avibactam/Ceftaroline Small molecule Gram-negative Phase 2 
 AZD5847 Small molecule M. tuberculosis Phase 2
AZD0914 Small molecule Gram-negative Phase 1
MEDI4893 Large molecule Gram-positive Phase 1
ATM-AVI (Avibactam/Astreonam) Small molecule Gram-negative Phase 1
MEDI3902 Large molecule Gram-negative Phase 1
Bayer Ciprofloxacin DPI (dry powder for inhalation) Small molecule Gram-negative Phase 3
Amikacin Inhale Small molecule Gram-negative Phase 3
Tedizolid Small molecule Gram-positive Phase 3
GSK Streptococcus pneumoniae Vaccine Gram-positive Phase 2 
GSK2140944 Small molecule Gram-positive Phase 2
GSK/Aeras Tuberculosis Vaccine M. tuberculosis Phase 2 
Janssen ExPEC Vaccine E. Coli Phase 1
Merck & Co / MSD Imipenem/MK-7655 Small molecule Gram-negative Phase 2
MK-3415/MK-6072 Large molecule C. difficile Phase 3
V114 – Pneumococcal Conjugate Vaccine Gram-positive Phase 2
Novartis Acellular pertussis booster Vaccine Gram-negative Phase 1
Acellular pertussis combos Vaccine Gram-negative Preclinical 
MenABCWY Vaccine Gram-negative Phase 2 
Staphylococcus aureus Vaccine Gram-positive Phase 1
Typhoid Vaccine Gram-negative Phase 2 
Group B streptococcus (GBS) conjugate Vaccine Gram-positive Phase 2 
Pfizer PF-06425090 Vaccine C. difficile Phase 1
PF-06290510 Vaccine Staphylococcus aureus Phase 2 
Roche RG7929 Large molecule Gram-negative Phase 2 




Sanofi ACAM-Cdiff Vaccine C.difficile Phase 3
Streptococcus pneumoniae Vaccine S. pneumoniae Phase 1 
Tuberculosis recombinant subunit Vaccine M. tuberculosis Phase 2 
Otsuka Delamanid Small molecule M. tuberculosis Phase 3 
Delamanid (paediatric) Small molecule M. tuberculosis Phase 2
Source: Rethinking the Way We Fight Bacteria, IFPMA, 2015. Supplied courtesy of IFPMA.
7It is important to note that a significant repository of potential antibiotics is undoubt-
edly present in (currently largely untapped) biodiversity. As the tools of, and sophis-
tication of, biotechnology advance, the potential for efficient, rapid and successful 
bioprospecting of such antibiotic candidates has increased.25 The recent case 
wherein “48 novel potential cationic antimicrobial peptides” were identified in the 
plasma of Varanus komodoensis (Komodo dragon), indigenous to Indonesia, is 
exemplary: “The antimicrobial effectiveness of eight… peptides was evaluated 
against Pseudomonas aeruginosa… and Staphylococcus aureus… with seven 
peptides exhibiting antimicrobial activity against both microbes and one only 
showing significant potency against P. aeruginosa.”26 Coherent, coordinated and 
equitable management of these biological resources and the potentially valuable 
IP that results from research and development will be crucial for sustainable con-
servation of, and widespread access to, subsequent new antibiotics.27 
Around 100 pharmaceutical and diagnostics companies (including support from 
major trade associations such as the IFPMA) declared their commitment to com-
bating AMR on January 21, 2016, at the World Economic Forum (WEF) in Davos.28 
They called on governments to work with them in developing new and alternate 
market structures to provide more dependable and sustainable market models. 
This includes new incentives for R&D, new mechanisms to ensure that the price 
of antibiotics reflects value, and payment models that reduce the link between 
profitability and volume of sales. The declaration also sets out the commitment 
by the companies across three broad areas:
1. reducing the development of drug resistance
2. increasing investment in R&D that meets global public health needs
3. improving access to high-quality antibiotics for all. 
Pharmaceutical companies have reinforced their commitment to the January 
2016 Declaration by issuing a Roadmap to Combat Antimicrobial Resistance29 
just ahead of the United Nations General Assembly on September 20, 2016, and 
pledged to deliver by 2020 to reduce AMR. 
25 McClory, Haley, and Stanley P. Kowalski, “Horses as sources of proprietary information: 
commercialization, conservation, and compensation pursuant to the Convention on Biological 
Diversity”, AgBioForum 17(2): 141-155, 2014. 
26 Bishop, Barney M., Melanie L. Juba, Paul S. Russo, Megan Devine, Stephanie M. Barksdale, 
Shaylyn Scott, Robert Settlage et al., “Discovery of novel antimicrobial peptides from Varanus 
komodoensis (Komodo dragon) by large-scale analyses and de-novo-assisted sequencing using 
electron-transfer dissociation mass spectrometry”, J Proteome Res. 16(4): 1470-1482, 2017. 
27 Multiple United Nations agencies work on the issue of fair and equitable sharing of benefits for 
the use of genetic resources. WIPO facilitates normative activities and provides capacity-building 
on the relationship between IP and access to, and benefit-sharing in, genetic resources and 




84. Preliminary survey of 
initiatives, partnerships 
and consortia engaged 
in the development of 
antibiotics
4.1 The WHO/DNDi Global 
Antibiotic Research & Development 
Partnership (GARDP)
The Global Antibiotic Research & Development Partnership 
was launched on May 24, 2016.30 The partnership aims to 
promote antibiotic product development and pilot incentive 
models that de-link the cost of R&D from volume-based 
sales and contribute to the conservation of, and access to, 
new antibiotic treatments. This provides an alternative to 
the traditional market-driven pharmaceutical approach, by 
focusing on products that the pharmaceutical industry will 
likely not develop for lack of commercial incentive.
The partnership goes back to a call in the WHO Global Action 
Plan on Antimicrobial Resistance (adopted in May 2015) for 
the creation of new partnerships to foster the development 
and conservation of antibiotics. To implement this part of the 
Plan, WHO and the Drugs for Neglected Diseases initiative 
(DNDi) are working in a new partnership that seeks to:
1. develop new antibiotic treatments addressing antimicro-
bial resistance 
2. pilot and test alternative incentive models that promote 
innovation and access
3. promote their responsible use for optimal conservation 
4. ensure equitable access for all by making products afford-
able, subject to a global conservation agenda
5. guarantee new products that are suitable for resource- 
limited settings.
The Partnership is working closely with all stakeholders – 
including pharmaceutical and biotechnology companies, other 
product development partnerships, academia, civil society, 
research organizations and health authorities – from coun-
tries of all income levels to develop new antibiotic treatments 
and to preserve them.
30 https://www.dndi.org/diseases-projects/gardp/ 
31 Ciabuschiet, Årdal, Findlay et al., WP2: Creation and testing of new economic models; Incentives to stimulate antibiotic innovation:  
The preliminary findings of DRIVE-AB; available at http://drive-ab.eu/wp-content/uploads/2016/06/WP2-Prereading-FINAL.pdf 
32 https://www.combacte.com 
33 https://www.medicalcountermeasures.gov/barda/cbrn/broad-spectrum-antimicrobials.aspx 
4.2 The Innovative Medicines Initiative (IMI)
The Innovative Medicines Initiative is Europe’s largest pub-
lic-private initiative aiming to speed up the development of 
better and safer medicines for patients. IMI supports collabo-
rative research projects and builds networks of industrial and 
academic experts in order to boost pharmaceutical innovation 
in Europe. One of its priorities is antimicrobial resistance. 
IMI’s program New Drugs 4 Bad Bugs (ND4BB) focuses 
on the scientific, regulatory and business challenges that 
are hampering the development of new antibiotics. ND4BB 
includes, inter alia, the creation of a pan-European network 
of excellence of clinical investigation sites, basic research to 
tackle, in particular, gram-negative bacteria, the development 
of a specific drug discovery platform for antibiotics, and the 
exploration of new economic models for antibiotic development 
(DRIVE-AB).31 AMR is a growing problem worldwide, and 
with few new drugs making it to the market there is an urgent 
need for new medicines to treat resistant infections. Also the 
Combatting Bacterial Resistance in Europe (COMBACTE) 
project forms part of the ND4BB initiative and aims to pioneer 
new ways of designing and implementing efficient clinical 
trials for novel antibiotics.32
4.3 The EU Joint Program Initiative 
on Antimicrobial Resistance
The EU Joint Program Initiative on Antimicrobial Resistance 
has been set up to pool national research efforts to spend 
public R&D resources more efficiently. 
Joint programming is used in different areas to overcome the 
fragmentation of national research programs, in particular 
where challenges are global in nature. The development of 
new preventative and therapeutic approaches is only one of 
many areas that form part of the Joint Programming Initiative 
on AMR. Research priorities are set out in the Strategic 
Research Agenda, and that agenda is implemented through 
launching joint calls for proposals to facilitate cross-border 
research projects. The focus of the Initiative is basic research; 
it does not currently finance product development. 
4.4 US Broad Spectrum 
Antimicrobials Program
BARDA’s Broad Spectrum Antimicrobials (BSA) Program was 
established in January 2010 and is focused on developing 
novel antibacterial and antiviral drugs for the treatment or 
prevention of disease caused by currently defined and future 
biological threats.33 The program recognizes that new antimi-
crobials are needed immediately to address the increasingly 
prevalent public health threat of antibiotic resistance, as well 
as the likelihood that AMR will complicate standard treatment 
of a wide array of infections. One of the main objectives is to 
revitalize the antimicrobial pipeline by providing incentives for 
9pharma and biotech companies to engage (or re-engage) 
in antimicrobial development (as mentioned in Section 2). 
Since that time around six companies have entered into col-
laborative partnerships with BARDA34 and they have invest-
ed hundreds of millions of dollars in supporting late-stage 
development, including through partnering with biotech and 
pharmaceutical companies. 
It is hoped that this strategy will ensure that novel antimicro-
bials progress through the development pipeline to approval, 
so that novel antimicrobials will be added to the arsenal of 
possible treatments available. One recent announcement 
was for a single treatment for multiple common infections 
that had entered the last stages of development.35 
4.5 The Combating Antibiotic 
Resistant Bacteria Biopharmaceutical 
Accelerator (CARB-X)
A further initiative was launched in July 2016 called CARB-X 
(Combating Antibiotic Resistant Bacteria Biopharmaceutical 
Accelerator). BARDA claims that it is possibly the largest 
public-private partnership in the world dedicated to preclinical 
antibiotic development. It involves seven partners in the UK 
and USA, and is backed with half a billion US dollars in funding. 
CARB-X partners are working together to set up a diverse 
portfolio with more than 20 high-quality antibacterial products.36
4.6 The UK independent Review 
on Antimicrobial Resistance
The UK independent Review on Antimicrobial Resistance, 
chaired by Jim O’Neill, was commissioned by the UK Prime 
Minister to analyze and propose concrete actions to tackle 
the global problems of antimicrobial resistance. The Review 
had to assess the extent to which market failure is responsible 
for the lack of investment in R&D of new antimicrobials and 
identify short-, medium-, and long-term interventions that 
could be undertaken by governments and other funders to 
stimulate investment in new antimicrobials for human use. 
In 2015, the Review published initial proposals to kick-start 
antibiotic drug discovery efforts at a global level. The propos-
als include channeling new funds into early-stage research, 
as well as creating a fund for product development to buy 
out major new breakthroughs. The latter could ensure a 
predictable and viable market for new antibiotics, providing 
an incentive for companies to invest.




37 Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, The UK Review on AMR, May 2016; available at https://amr-review.org 
38 http://amrcentre.com, launched May 2016.
39 G20 Agriculture Ministers Meeting Communiqué, June 3, 2016; available at http://www.g20chn.org/English/Documents/Current/201606/
t20160608_2301.html 
40 WHO Global action plan on antimicrobial resistance, Options for establishing a global development and stewardship framework to support the 
development, control, distribution and appropriate use of new antimicrobial medicines, diagnostic tools, vaccines and other interventions, A69/24 
Add.1., May 13, 2016. 
41 Jinks et al., “A time for action: antimicrobial resistance needs global response”, WHO Bulletin, 2016. 
42 www.un.org/pga/71/wp-content/uploads/sites/40/2016/09/DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf 
43 www.un.org/pga/70/events/high-level-meeting-on-antimicrobial-resistance 
The Review published its final report on May 19, 2016 and 
proposed nine interventions ranging from a global awareness 
campaign to improved sanitation and the development of 
new diagnostics, medicines and vaccines.37 Two particular 
interventions worthy of note are the creation of a global inno-
vation fund for early-stage and non-commercial R&D, and 
better incentives to promote investment for new drugs and 
improving existing ones. Both of these will be considered in 
more detail later in this paper. 
As a result of the review, the UK launched The AMR Centre, 
which forms a key part of the UK’s response to AMR. The 
AMR Centre is a joint public-private initiative to support/
accelerate the development of new antibiotics and diagnos-
tics through a fully integrated development capability, offering 
translational R&D from pre-clinical hits through to clinical 
proof of concept.38
4.7 Additional remarks
The above list is not intended to be exhaustive and there may 
be other valuable initiatives that have not been mentioned. 
However, it is noted that the majority of initiatives involved 
developed countries, although there has been some politi-
cal will to support focus on AMR from the G20 countries.39 
Although the enhanced focus is warmly welcomed by many, 
there is an increased need to ensure effective alignment and/
or coordination within the AMR landscape in order to fill the 
necessary gaps and avoid duplication. There also needs to be 
an assessment of the contribution and value of each initiative 
so that successful platforms can be enhanced, while platforms 
that fail to meet expectations can be re-tasked or refocused. 
WHO has proposed options for establishing a global devel-
opment and stewardship framework.40 However, countries 
will need to be open to sharing information and allowing 
their national programs to be shaped and influenced for 
global success41 rather than national interests, if the shared 
goal is to be realized. The Political Declaration42 of the High-
Level Meeting of the United Nations General Assembly on 
Antimicrobial Resistance on September 21, 2016, will help to 
achieve this by summoning and maintaining strong national, 
regional and international political commitment in addressing 
antimicrobial resistance comprehensively and multi-sectorally, 
and to increase and improve awareness.43
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5. Global experience
A review of the literature revealed significant differences in the way countries use antibiotics. For 
example, in Europe, the Scandinavian countries use relatively few antibiotics, and consequently have 
very low levels of resistance. On the contrary, countries like Greece, Italy and a number of Eastern 
European countries are relatively heavy users and hence display pronounced levels of antibiotic resis-
tance. Many other regions and countries, like India, China and the Americas, are heavy users, and 
also use antibiotics as animal growth promoters. Hence the same huge differences are seen in animal 
production-related use as some countries are adding antibiotics to animal feed as a matter of course. 
Evidence shows that in low-income and middle-income countries (LMICs), antibiotic use is increasing 
with rising incomes, high rates of hospitalization, and high prevalence of hospital infections.44 However, 
where there are weak health systems, the effect of AMR on health and economics is largely under-
estimated and incompletely understood.45 It largely follows that effective access is hindered where 
there are weak health systems. At least two-thirds of childhood mortality is related to infections, and 
children are therefore probably more vulnerable than adolescents and adults.46 
The global market value of veterinary drugs increased from USD 8.7 billion in 1992 to USD 20.1 billion 
in 2010, and in 2018 is anticipated to reach USD 43 billion.47, 48, 49 Overuse of antibiotics in animals 
remains a key problem. For example, China is one of the world’s highest users of the antibiotic colistin 
in agriculture and it is suggested that this heavy use has resulted in resistance.50 Resistance travels 
fast and hence a Chinese problem fast becomes a global one. Therefore no country can successfully 
tackle AMR by acting in isolation.51
Other problems include overprescribing or unregulated use of antibiotics. In China, for instance, hos-
pitals and clinics receive financial incentives for prescribing, and antibiotics are overused as a result.52 
Some countries allow pharmacies to sell antibiotics without prescription and people buy them even 
for diseases that antibiotics cannot treat, such as malaria.53
There are significant similarities within all countries as there is a need for an effective health system. 
Ensuring access and appropriate use depends on multiple factors operating within a well-functioning 
and well-managed national healthcare system:
• rational selection and use
• affordable prices
• sustained financing
• reliable health supply systems
• robust regulation and enforcement systems.54
44 Ibid. 13. 
45 Antibiotic Resistance – The Need for Global Solutions, The Lancet Infectious Diseases Commission, 2013. 
46 Liu et al., for the Child Health Epidemiology Reference Group of WHO and UNICEF, “Global, regional, and national causes 
of child mortality: an updated systematic analysis for 2010 with time trends since 2000”, Lancet 2012; 379: 2151–61. 
47 Global Industry Analysts, “Animal health market to hit $43 billion in five years”, Western Farm Press, August 13, 2012; 
available at http://westernfarmpress.com/management/animal-health-market-hit-43-billion-five-years
48 Van Boeckel, T.P., C. Brower, M. Gilbert, et al., “Global trends in antimicrobial use in food animals”, Proc Natl Acad Sci 
USA, 2015; 112: 5649–5654. 
49 QYResearch Medical Research Centre, The Global Polymyxin Industry Report, 2015; available at www.qyresearch.com 
50 Yi-Yun Liu, Yang Wang, et al., “Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and 
human beings in China: a microbiological and molecular biological study”, Lancet 2016 Volume 16: 161–168. 
51 Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, The UK Review on AMR, December 
2014; available at https://amr-review.org 
52 Reardon, “Antibiotic resistance sweeping developing world – Bacteria are increasingly dodging extermination as drug 
availability outpaces regulation”, Nature, May 6, 2014. 
53 Ibid. 50. 
54 Eveline Wesangula, Fostering access to, and appropriate use of, antibiotics – a balancing act, WHO, WIPO, WTO 
Technical Symposium on Antimicrobial Resistance: How to Foster Innovation, Access to, and Appropriate Use of 
Antibiotics, October 25, 2016; available at www.wipo.int/meetings/en/2016/wipo_wto_who_technical_symposium.html 
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GARDP held a regional workshop in Cape Town, South Africa, in September 2016.55 Forty-five par-
ticipants from 11 African countries participated in the meeting.
The following needs and challenges were noted:
• Many African countries have weak health systems.
• Africa has a high burden of disease, e.g. TB and malaria, and malnutrition is a major problem.
• There is a scarcity of data on AMR.
• Policies and regulations that make sense and ensure stewardship and access at national level are 
needed.
• There is a need to undertake R&D to address ESKAPE56 pathogens, as well as the resistant sexually 
transmitted infections and resistant infections along with the emerging threat from Candida Auris.
The priorities that were identified included:
• rapid point-of-care tests to distinguish bacterial from viral infections, as well as pathogen-specific tests
• diagnostics support for stewardship 
• stewardship cannot be seen as a national effort – it must be regionally harmonized
• establishment of an African-driven and coordinated AMR clinical trial network that should capitalize 
on several existing networks and create centres of excellence for trials
• dissemination of national guidelines to medical practitioners and hospitals would help support stan-
dardization of care. 
In Kenya, it was identified that the best immediate approaches for appropriate use include:
• increased use of vaccines that reduce disease and therefore antibiotic demand
• improved infection control, including procedures (e.g. hand hygiene, checklists) and information 
guidelines, particularly in hospitals
• education and public awareness campaigns for providers and consumers. 
Three additional important approaches, which are not immediately implementable, are:
• increased use of improved diagnostics, to better target antibiotic use
• resolution of supply-chain constraints and failures
• economic incentives to encourage better use of antibiotics.57
Poor countries often suffer from lack of regulations for antibiotics, leading to access to substandard 
or falsified antibiotics. Substandard antibiotics often have a lower dosage of the active ingredient that 
results in increased resistance.58 It is clear that policies for appropriate supervision and control by reg-
ulatory agencies are needed to prevent the supply of expired, substandard and counterfeit medicines.
Evidence suggests that when antibiotics are available the issues are the same for all countries. Overuse 
leads to greater levels of resistance and hence effective antibiotic stewardship is crucial. However, 
sustainable access to effective antibiotics, both existing and new, remains a key challenge.
55 Meeting report Antimicrobial Resistance (AMR) Research and Innovation: Addressing Africa’s Regional Priorities, Cape 
Town Lodge Hotel, Cape Town, South Africa, September 1, 2016. 
56 ESKAPE stands for the following pathogens: enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, 
acinetobacter baumannii, pseudomonas aeruginosa and enterobacter. See: Helen W. Boucher, George H. Talbot, John S. 
Bradley, John E. Edwards, David Gilbert, Louis B. Rice, Michael Scheld, Brad Spellberg, John Bartlett, “Bad Bugs, No 
Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America”, Clin Infect Dis (2009) 48 (1): 1-12., DOI: 
https://doi.org/10.1086/595011
57 Samuel Kariuki, Situational Analysis and Recommendations: Antibiotic Use and Resistance in Kenya, August 2011.
58 Michael A. Kohanski, Mark A. DePristo, James J. Collins “Sublethal antibiotic treatment leads to multidrug resistance via 
radical-induced mutagenesis”, Molecular Cell, Volume 37, Issue 3, 311-320, February 12, 2010. 
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6. Intellectual property 
related issues
This section looks at the role of IP – both in terms of incentiv-
izing R&D and preventing possible generic companies from 
entering the market. 
IP is a part of the enabling environment for innovation and 
as such a policy tool to incentivize or enable innovation by 
providing a fixed period of exclusivity for full public disclo-
sure. However, the patent system can only contribute as an 
effective incentive mechanism if there is, or will be, sufficient 
market drivers. In the normal business model of medicine 
development, the innovator calculates a price based on a 
number of factors - including market dynamics, cost of R&D, 
etc. Once a patent expires, providing regulatory approval 
has been obtained, generic companies are able to sell the 
medicine and compete based on sales volume. 
There are a number of problems with this model when 
addressing AMR/MDR. Firstly, pharmaceutical companies 
are reluctant to invest in antibiotic R&D because the returns 
are significantly lower than for other areas, leading to many 
companies exiting the market. There are unique problems 
when developing the next generation of antibiotics:
• Limited use. New antibiotics were often reserved as drugs 
of “last resort” and used “sparingly” for “short” courses of 
treatment. In contrast, treatments for mental illnesses or 
cancer may last for several weeks, months or even years, 
providing greater opportunity for those treatments to deliver 
a return on investment.
• Low price. Existing antibiotics are very cheap and are 
generally only used for a short period of time. 
• Short lifespan. Antibiotics can have a short working lifes-
pan, as resistance may develop to compounds in a relatively 
short period of time, sometimes at the clinical trial stage. 
• Clinical trials. Conducting clinical trials of antimicrobials 
is difficult because it is often not clear which pathogen was 
affecting a patient, diagnosis time can be lengthy and high-
ly selective patient populations are required. If the value 
of a new antibiotic can only be demonstrated on patients 
who display infection resistance then clinical development 
becomes prohibitively lengthy and expensive until resis-
tance becomes widespread. 
59 Renwick, M.J., V. Simpkin and E. Mossialos, International and European Initiatives Targeting Innovation in Antibiotic Drug Discovery and 
Development, The Need for a One Health – One Europe – One World Framework, Report for the 2016 Dutch Presidency of the European Union. 
60 Ibid. 31. 
61 Securing New Drugs for Future Generations: The Pipeline of Antibiotics, The Review on Antimicrobial Resistance, May 2015. 
62 Rethinking the Way We Fight Bacteria, IFPMA, 2015. 
63 Antimicrobial Resistance in G7 Countries and Beyond, OECD, 2015. 
64 Renwick, M.J., V. Simpkinand E. Mossialos, “A critical assessment of incentive strategies for development of novel antibiotics”, LSE Health, London 
School of Economics and Political Science, October 31, 2014. 
65 Ibid. 15. 
66 London Boston Consulting Group, Breaking through the Wall – A Call for Concerted Action on Antibiotics Research and Development, 
commissioned by the German Federal Ministry of Health, February 2017. 
Despite the clear value of antibiotics for society, the incen-
tives to develop them are notably small. This led to less than 
5 percent of venture capital investment in pharmaceutical R&D 
between 2003 and 2013 being allocated to AMR.59 Creating 
a vibrant and sustainable pipeline remains a primary objec-
tive and there are numerous initiatives underway to develop 
incentives to stimulate antibiotic innovation. The recently 
launched DRIVE-AB initiative has already published a short-
list of push and pull models/mechanisms to incentivize R&D.60
Generally, innovators and generics are commercially incen-
tivized to sell high volumes of product. This cannot work in 
the case of AMR/MDR as the goal is to provide access to 
only those patients who absolutely need the state-of-the-art 
treatment.61 Low sales generally lead to an unsustainable 
business model, but high levels of sales would result in 
overconsumption and contribute to high levels of resistance. 
Hence, simply increasing developer return on investment 
(ROI) does not address the problem directly. 
Therefore, alternative mechanisms are required to help 
de-risk62 or de-link63 companies’ initial investment. 
Numerous experts have proposed antibiotic business mod-
els that reinforce conservation efforts by completely sev-
ering a developer’s ROI from sales volume and price. This 
concept is known as “de-linkage” and is beneficial for three 
key reasons. Firstly, it provides developers with a concrete 
ROI that is extraneous to the market. Secondly, it removes 
the motivation for developers to overmarket their antibiotic. 
Thirdly, it facilitates access to new antibiotics for those who 
need them most.64 An additional possible benefit is that it 
may encourage collaboration and coordination (avoiding 
duplication) since incentives can be provided to consortia. 
Other experts advocate the use of demand-side antibiotic 
usage fees to internalize the negative externalities accompa-
nying antibiotic use. This fee can then be used to finance other 
incentive mechanisms such as milestone payments or end 
prizes.65 For example, the Boston Consulting Group’s report 
to the German Government recommended the creation of: 
• a Global Research Fund – to support academics and SMEs 
(starting budget of USD 200 million)
• a Global Development Fund – to support promising drug 
candidates (annual budget of USD 200 million)
• a Global Launch Reward of USD 1 billion for a successful 
product that meets certain criteria.66 
13
The UK Review on AMR proposed a system of market entry 
rewards (MERs) of around USD 1 billion per drug for effective 
treatments, whether they are based on new or old drugs that 
work against resistant pathogens in areas of most urgent 
need.67 This would be funded by an “antibiotic investment 
charge”, which would be imposed widely on the pharmaceu-
tical sector and applied on a “pay or play” basis, meaning 
companies could either pay the charge or invest in R&D that 
is deemed useful for AMR. However, some worry that this is 
not the best method of encouraging R&D. Many companies 
are simply not geared up to commence AMR R&D and hence 
may regard this as simply another tax.68 Irrespective of how 
MERs would be financed, it is important to work out how IP 
associated with such a prize mechanism could be handled. 
For example, would IP rights simply be transferred on receipt 
of the reward or would there be a sliding scale with a limited 
sub-license at the other end of the compendium? The most 
suitable approach could be guided by a number of factors 
including complexity and cost of manufacture, volume required, 
securing of regulatory approval in target countries, etc. 
In the case of antibiotics, there is a need for restricted use, 
hence limited market opportunity. One proposal has been to 
create the possibility of transferrable IP rights.69 This would 
mean that a developer of a new and high-value antibiotic 
would be rewarded with the opportunity to extend patent term 
on another medicine to enable recuperation of R&D spent, 
given that the market for any new antibiotic will likely remain 
very small. This idea has received a negative response from 
the NGO community, which feels that the ultimate price of 
an extended “blockbuster”70 medicine would outweigh the 
cost of antibiotic R&D.71
A further idea would be to give antibiotic developers exchange-
able “vouchers” as an incentive. While one type of voucher 
relates to a transferrable IP right, the other type relates to a 
priority review of any medicine waiting approval by a regulator. 
This would mean that a medicine could receive accelerated 
review with a view to rapid placement in the market. The 
recipient developer could either use it for one of their own 
medicines or sell it to another developer. Although this would 
clearly provide an incentive, its value would diminish if there 
were a significant increase in voucher availability.72 Such an 
approach might be considered for the creation of new and 
effective diagnostic tests. As noted above, such a test would 
be highly valuable in ensuring appropriate antibiotics use and 
monitoring/surveillance of AMR/MDR. 
67 Ibid. 37. 
68 Schoonveld, The UK’s Pay-or-Play Solution: A Horribly Flawed Idea, May 20, 2016. 
69 Ibid. 8. 
70 A blockbuster medicine is one that generates annual sales of at least USD 1 billion for the company that creates it. 
71 Approaches to Simulating Innovation for Development of New Antibiotic Drugs, KEI, 2013; available at www.who.int/phi/implementation/annex_
antibiotic_research_development.pdf?ua=1 
72 Outterson, K., and A. McDonnell, “Funding antibiotic innovation with vouchers: Recommendations on how to strengthen a flawed incentive policy”, 
Health Affairs, 2016, 35, 5. 
Figure 2: 
Patent filings by public and private 
organizations, January 2007-May 2017
Source: Stanley Kowalski, patent search on May 12, 2017 in Derwent 

















7. High-level patent trends 
over the past 10 years 
Patent trends for AMR over the past 10 years were analyzed to determine which entities have been 
most active. Table 2 shows the list of the top 25 applicants/assignees of patent documents between 
2007 and 2017. Of the identified documents, 68 percent pertain to filings from private entities and 
28 percent to public institutions (Figure 2). Among the putative patent owners are 11 pharmaceutical 
companies, four biotechnology companies, eight public sector research organizations and two other 
entities (Figure 3).
Table 2: 
Antibiotic patent data with putative owners of intellectual property 
rights by the world’s top 25 pharmaceutical companies and public 
research institutions in the area of antibiotics, January 2007-May 2017
Twenty five top Applicants/Assignees Patent Documents  
(applications, grants, etc.) 
Country
Private sector entities
Genentech Inc. 324 US
Merck Sharp & Dohme (incorporating Schering Corp.) 229 US
Vertex Pharma 222 US
Immunomedics Inc. 204 US
Abbott Laboratories 138 US
GSK (incorporating Smithkline Beecham Corp.) 132 UK
Novartis AG 115 CH
Idera Pharmaceuticals INC. 112 US
Celgene Corp. 111 US
Foamix Ltd. 109 US
Amgen Inc. 106 US
Medtronic Vascular Inc. 106 US
Abbvie Inc. 96 US
The General Hospital Corporation 93 US
Paratek Pharmaceuticals Inc. 90 US
Pfizer (incorporating Wyeth Corp.) 75 US
Hoffmann-La Roche 70 CH
Public sector entities
University of California 246 US
University of Texas 149 US
Tufts College 124 US
Centre national de la recherche scientifique 117 FR
Johns Hopkins University 102 US
Massachusetts Institute of Technology 93 US
Boston University 75 US
Harvard College 74 US
Source: Stanley Kowalski, patent search on May 12, 2017 in Derwent Innovation (formerly Thomson Innovation).
Search Parameters: combined US granted, US applications, EPO granted, EPO applications and Patent Cooperation Treaty 
(PCT); search terms: IPC = A61K and Claim = Antibio! and Priority Date: 2007 to 2017. The IPC A61K appears to prevail on the 
most relevant results (oral antibiotics patents) that were found initially via a simple keyword search approach. A subsequent 
search sought to refine the results, i.e., via a hybrid keyword (limited to claim) combined with (“and”) the identified most-
prevalent IPC. This is a simple Boolean strategy using set theory to delineate data (restricted keyword plus IPC) and then 
identify a combined subset which has a higher likelihood of having relevant results.
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Figure 3: 
Patent filings by type of organization, January 2007-May 2017
Source: Stanley Kowalski, patent search on May 12, 2017 in Derwent Innovation (formerly Thomson Innovation).
The data show that patenting activity of the last 10 years is relatively strong. However, this does not 
correlate to the number of new antibiotics produced over the same period and patenting tends to focus 
on existing classes of antibiotics, with more patent families directed towards the penicillin antibiotics 
than any other known class. This is an interesting trend that shows that they still have a significant role 
in tackling bacterial infections despite widespread resistance and their repeated use. This increment 
developed within such a well-known existing class shows that there remains a strong possibility of 
new therapeutic application.
The US has the highest number of patent applications since 2004 – almost twice as many as Europe 
(via the European Patent Office (EPO)) and China (Figure 4). The penicillin class of antibiotics attracts 
the highest number of patent applications (families) (Figure 5) and, although the pioneering class was 
discovered almost 90 years ago, it remains relevant for treatment today.
Figure 4: 
Total patent applications relating to antibiotic 
research in top jurisdictions, 2004–2015
Source: Medicines for rare diseases, vaccines and antibiotics, Marks & Clerk, Life Sciences Report, 2015.
Although some large companies have abandoned research in AMR/MDR and other communicable 
disease areas, a number of large and small companies are active in this field. The model is that they 
undertake the research and early development but then license the candidate compound(s) to larg-
er companies, which then undertake the risk and expense of completing the medicine development 
process. For example, Iterum was set-up in March 2016 with an antibiotic licensed from an unnamed 
pharmaceutical company and joins a steadily growing group of biotechnology companies like Spero 
and Cidara, which have been pushing ahead in the clinic with anti-infectives designed to meet the AMR 




























































































































































































































Families of patent applications relating to research into specific known 
classes of antibiotics, 2004–2015
Source: Medicines for rare diseases, vaccines and antibiotics, Marks & Clerk, Life Sciences Report, 2015.
Table 3: 
Current licensing agreements
Date Licensor Licensee Details
Jan 2014 AstraZeneca 
UK
FOB Synthesis License covers combinations of the two companies’ experimental 
medicines. AZ plans to test its own beta lactmase inhibitor alongside 
the smaller company’s carbapenem medicines
Sept 2015 AstraZeneca 
UK
US Dept. of Health 
& Human
Collaboration. Public-private partnership. Combining antibiotics to 
tackle multi-drug resistant bacterial infections
May 2009 Aurobindo Pharma, 
India
Pfizer Licence includes antibiotics
May 2009 Claris LifeSciences, 
India
Pfizer Licence includes anti-infectives
March 2014 Discuva 
UK
Roche Worldwide collaboration and license agreement for the discovery 
and development of new antibiotics to treat life-threatening infections 
caused by multi-drug resistant Gram-negative bacteria using Discuva’s 
proprietary SATIN technology platform
Jan 2015 Fedora Pharmaceuticals 
Canada 
With Meiji Seika
Roche Worldwide license outside Japan for OP0595, a beta-lactamase 
inhibitor in phase I clinical development for multidrug resistant bacterial 
infections




License provides exclusive rights to develop novel macrolide antibiotics
Oct 2015 Harvard’s Office of 
Technology Development
Opsonix Exclusive license to develop a recombinant human protein derived from 
mannose binding lectin to treat blood-born diseases, such as sepsis
April 2011 Janssen Pharmaceuticals Furiex 
Pharmaceuticals
Acquired full licensing rights to develop broad-spectrum 
fluoroquinolone antibiotic




Roche Worldwide license outside Japan for OP0595, a beta-lactamase 
inhibitor in phase I clinical development for multidrug resistant bacterial 
infections




License for fidaxomicin, which is a novel antibiotic used to treat  
C. difficile
2014 Phylogica / Genentech Roche Research and licensing agreement, access to drug discovery platforms 
for novel antibiotics
April 2014 Spero 
USA
Roche Partnership option to acquire a drug candidate from start-up Spero
July 2014 Trius Therapeutics Bayer Licensing of torezoid phosphate, a phase 3 antibiotic 












































































































































































































8. Opportunities for innovation 
and intellectual property 
systems 
A suggested area of particular interest is the exploration of different business mod-
els.73 For example, ideas include the creation of a global antibiotics public-private 
partnership; a global antibiotics fund, which could pool all existing funds under one 
umbrella; a global procurement and distribution entity;74 and a global governance 
system to ensure effective stewardship and rationale use.75 
There are three possible non-exclusive options for the creation of the next gener-
ation of antibiotics (including AMR-associated vaccines and diagnostics):
1. private sector-driven R&D through the creation of new push and pull mechanisms
2. public-private partnerships where risks and rewards are shared and resources 
are pooled 
3. public funding where R&D priorities and associated implementation is agreed 
at international/regional/national levels. 
All the above options may work in developing new treatments for AMR/MDR. 
However, whichever option or combination of options is used, it is crucial that 
there is an effective international system of governance that facilitates rational 
use at a national level, otherwise high levels of resistance are likely to continue. 
Under option 1, there is a crucial need to develop a pool of incentives and infor-
mation resources for antibiotic development. It is worth investing in the detailed 
exploration of IP-linked incentive mechanisms that would clearly highlight the 
benefits and considerations of each approach. The role of new and effective 
vaccines and diagnostics will be important in preventing disease and ensuring 
that the right treatment options are identified. Following on from the industry 
declaration and roadmap,76 a further policy position was launched at the World 
Economic Forum (WEF) in 2017 concerning the development of sustainable mod-
els to overcome the challenging economics of antimicrobial R&D. A key focus is 
on pull incentives covering:
• market entry rewards
• insurance license models
• IP mechanisms.77 
The B20 Health Initiative also included recommendations on AMR but went 
broader than economic incentives and included reference to supporting GARDP, 
harmonizing regulatory environments, development of guidelines for appropriate 
use and advanced capacity building.78 The G20 Leaders’ Declaration supported 
this approach by calling for the creation of a new international R&D Collaboration 
Hub – to maximize the impact of existing and new antimicrobial basic and clinical 
research initiatives, and to further examine practical market incentive options.79
73 Changes in the innovation landscape and new business models in medical innovation were 
also discussed at the WHO, WIPO, WTO joined technical symposium on Medical Innovation 
– Changing Business Models on July 5, 2013; see Wai, T. and P. Stevens, 2014, The Changing 
Landscape of Medical Innovation: How Have Business Models Responded?, Global Challenges 
Brief, WIPO: Geneva; available at www.wipo.int/meetings/en/2013/who_wipo_ip_med_ge_13 
74 Securing New Drugs for Future Generations: The Pipeline of Antibiotics, The Review on 
Antimicrobial Resistance, May 2015. 
75 Business Model Options for Antibiotics, The Royal Institute of International Affairs (Chatham 
House) and the Big Innovation Centre, February 2015. 
76 Ibid. 28 and 29. 
77 Sustainable models to overcome the challenging economics of antimicrobial R&D, IFPMA Policy 
Position, January 18, 2017. 
78 B20 Health Initiative, Stepping Up Global Health: Towards Resilient, Responsible and 
Responsive Health Systems, May 18, 2017. 
79 G20 Leaders’ Declaration, Shaping an interconnected world, Hamburg, July 7-8, 2017; available 
at https://www.g20.org/gipfeldokumente/G20-leaders-declaration.pdf
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WIPO Re:Search80 is a consortium of public and private partners that aims to 
accelerate the discovery and product development of medicines, vaccines, and 
diagnostics to create new solutions for people affected by neglected tropical 
diseases, malaria and tuberculosis by making IP and know-how available to the 
global health research community. A Partnership Hub managed by BIO Ventures 
for Global Health (BVGH) connects partners and brokers research collaborations. 
WIPO Re:Search provides a mechanism which illustrates how IP issues can be 
successfully handled to support developing and maintaining research partnerships. 
WIPO Re:Search collaborations are based on Guiding Principles that establish 
essential parts of the prospective license agreement, thereby considerably reduc-
ing the effort and costs of negotiating the license agreement. 
WIPO Re:Search might serve as a case study that provides the experience of 
partnering and connecting antibiotic researchers and developers and supporting 
partnership building in the area of neglected tropical diseases, malaria and TB. 
The role of the WIPO Re:Search Partnership Hub could be a model for AMR/MDR 
research to proactively identify and facilitate collaborations that connect industry to 
academic and other non-profit researchers. Such a model could be the principal 
source of information on antibiotic research and development around the world, 
so that potential partners could explore collaboration on existing projects or iden-
tify possible gaps. The experiences gained could serve GARDP, which seeks to 
fill R&D gaps, particularly where a commercial incentive is insufficient. A WIPO 
Re:Search-inspired platform might be used where candidate compounds might be 
identified and shared in order to maximize collective input from potential partners. 
The UK Review on AMR has proposed a global innovation fund but noted that 
a number of existing funding mechanisms exist.81 Such funding has been made 
available through various initiatives (as mentioned in Section 3) but there is a lack 
of coordination and collaboration, and substantial gaps remain. A global fund 
would ensure a holistic approach, but agreeing to common R&D priorities may 
be challenging given the diverse burden of AMR/MDR around the world. How 
to create government financing mechanisms has been discussed in WHO for 
a number of years, with ideas ranging from taxing financial transactions or use 
of commercial passenger airliners to commitments of percentages of GDP.82 A 
number of mechanisms are referred to in Section 6. However, it is often the case 
that government funders prefer to support initiatives within their own countries 
and/or regions, where control is easier and other benefits, such as training of the 
new generation of scientists and researchers, can be realized.83 The unique threat 
posed by AMR/MDR provides a strong incentive to overcome these challenges 
but it will take time and commitment to fully establish and operationalize. WHO, 
as part of the implementation of the Global Action Plan, is currently starting a 
project to identify global R&D needs. This is necessary to guide joint efforts such 
as CARB-X or the WHO/DNDi GARDP initiative to address global R&D needs.
80 www.wiporesearch.org 
81 Ibid. 37, page 49. 
82 WHO, Report of the Consultative Expert Working Group on Research and Development: 
Financing and Coordination: Research and Development to Meet Health Needs in Developing 
Countries: Strengthening Global Financing and Coordination, April 2012. 
83 Ben S. Bernanke, Promoting Research and Development: The Government’s Role, 2011. 
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9. Access to new-generation 
antibiotics and stewardship 
Any stewardship framework needs to ensure access for patients who need treat-
ments while preventing inappropriate use. An effective health system is essential 
for both access and stewardship so that patients can be appropriately diagnosed, 
treated (being made aware of the crucial importance of medicine adherence), and 
cured. WHO has produced an options document that details key considerations 
for the establishment of a global development and stewardship framework. This 
includes the type of instrument that could be used, scope of medical products, 
how to define and promote appropriate use, development of new treatments, tools 
and vaccines and affordable access.84 
The Medicines Patent Pool (MPP) has proven a successful innovation and access 
model in the area of HIV/AIDS. Based on this success, the mandate of the pool 
has expanded to include other communicable diseases such as Hepatitis C. The 
value of this model is that a degree of antibiotic stewardship could readily be includ-
ed as part of a licensing arrangement.85 The MPP, if deciding to enter the field of 
antimicrobial medicines, could establish licensing agreements for AMR-related 
vaccines and diagnostics. Prevention is always better than cure and effective 
diagnosis is crucial to ensure appropriate use. Countries receiving new-genera-
tion antibiotics would first need to be assessed based on need. Applications for 
new-generation antibiotics could be independently assessed by a panel of technical 
experts, following a similar model to the Green Light Committee (GLC) Initiative,86 
which assesses country applications for access to second-line anti-tuberculosis 
medicines for the effective treatment of MDR-TB. 
In addition to the above, patent-linked licensing arrangements could be used as 
an enforcement mechanism to ensure compliance with stewardship requirements. 
Failure to adhere to predetermined principles of stewardship undermines the 
overall objective, and hence could lead to the restriction or prevention of future 
supply to the entity that violates the terms of the agreement. It is crucial that an 
effective sanction is in place, with the hope that implementation of such a sanction 
will not be necessary. 
The MPP has a similar mechanism with generic producers who are members of 
the pool. Failure to utilize the license through manufacture and sufficient supply 
of the associated product ultimately results in withdrawal of the license.87 
There are opportunities for collaboration between different entities and initiatives 
where expertise, best practice and networks could be combined to achieve shared 
goals. For instance, platforms could be explored where various stakeholders could 
come together for the development of combination treatments or other important 
formulations. 
84 Ibid. 41. 
85 Kieny, M.P., Creating and Intergovernmental Consortium for New Antibiotics: A New 
Development Model, 2015; Ibid. 18. 
86 The Green Light Committee (GLC) Initiative, frequently asked questions document. 
87 For example, Sublicense and Technology transfer Agreement between Bristol-Myres Squibb, the 
Medicines Patent Pool Foundation and Cipla Ltd, December 14, 2015 (Article 12.3, page 16). 
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10. Conclusion
Ultimately the most effective way to tackle AMR/MDR is to provide a global 
framework88 that includes the full range of activities - including disease prevention, 
awareness campaigns, improved sanitation, surveillance and monitoring - that are 
able to be implemented effectively at a national level. But the development of new 
diagnostics, medicines and vaccines remains a critical component that requires 
new or adapted funding mechanisms and incentive systems. 
As with many complex problems, there is no one-size-fits-all solution and both 
public and private involvement, often in partnership, will be required to meet the 
challenge. Maximizing the collective benefit from the significant range of experience, 
expertise and resources available will require effective coordination, collaboration 
and alignment at global and local levels. 
The United Nations Ad-hoc Interagency Coordination Group on Antimicrobial 
Resistance (AMR), established by the United Nations Secretary-General as man-
dated by UN Resolution 71/3 of October 5, 2016, began its work in May 2017.89 It 
draws on expertise from all relevant stakeholders and is expected to report to the 
General Assembly and make recommendations, including on options to improve 
coordination. The Group can contribute to providing the necessary political sup-
port. Such support should include ministries of health, finance and agriculture, 
given the potentially wide range of health, economic and social impacts involved. 
This work can be complemented by formulating mechanisms that drive innovation 
for results to incentivize success, while feeding expertise and experience into 
stewardship and access efforts. Consideration should be given to how IP could 
be used in any reward or prize system for AMR/MDR R&D – both in terms of 
incentive and governance. 
There are numerous frameworks that encourage cooperation and collaboration 
between the public and private sector. Nevertheless, there is a need to connect 
and synergize the identified best practice associated with these initiatives to the 
challenges posed by AMR/MDR. WIPO Re:Search and the Medicines Patent Pool 
are both strong examples of what can be achieved where normal market drivers 
are limited or where complexities of collaboration exist. Policymakers should 
consider how these mechanisms enable the sharing of experience, expertise and 
know-how, reduce transactional costs, simplify licensing arrangements and terms 
and enable the sharing of best practice. These findings and insights should be 
extracted, refined and applied in the area of AMR/MDR so that the unique chal-
lenges of innovation, access and appropriate use can be effectively addressed.
AMR/MDR will impact all countries, but particularly those where health systems 
need to be strengthened. Collaborative and urgent action should be seen as a 
priority but finding a way to achieve this in practice will be the next important hurdle. 
88 See, for example, ibid. 40 for a development and stewardship framework. 
89 www.who.int/antimicrobial-resistance/interagency-coordination-group
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